SkinHealth Q2 Sales Drop 7.8%, Guides Q3 EBITDA to $5–$7M Amid Turnaround

summarizeSummary

SkinHealth Systems posted a 7.8% sales decline in Q2 2026 but improved adjusted EBITDA to $17.0 million. Q3 guidance implies further sequential deterioration, with adjusted EBITDA expected at just $5–$7 million.

check_boxKey Events · Earnings and Guidance · SKIN

• Q2 Sales Decline 7.8%

  Net sales fell to $72.1 million from $78.2 million a year ago, with delivery system placements dropping to 770 from 957.

• Net Loss Swings to $(2.7)M

  Q2 2025 included an $18.1 million gain on debt exchange; excluding that, the underlying loss narrowed, and adjusted EBITDA improved to $17.0 million from $13.9 million.

• Q3 Guidance Implies Steep Sequential Drop

  Company guided Q3 net sales to $65–$70 million and adjusted EBITDA to $5–$7 million, down sharply from Q2's $17.0 million, signaling worsening trends.

• FY2026 Outlook Lowered

  Full-year guidance revised to net sales of $280–$290 million and adjusted EBITDA of $39–$46 million, reflecting continued sales pressure.

auto_awesomeAnalysis · SKIN · Industrial Applications And Services

SkinHealth Systems reported a 7.8% decline in Q2 net sales to $72.1 million, driven by lower delivery system placements (770 vs. 957 a year ago). Net loss was $(2.7) million, swinging from a $19.7 million profit in Q2 2025 that was boosted by a one-time debt exchange gain. Adjusted EBITDA rose to $17.0 million from $13.9 million, reflecting cost discipline and improved gross margins. The company issued Q3 guidance of $65–$70 million in sales and $5–$7 million in adjusted EBITDA, well below the Q2 run rate, signaling continued headwinds. Against a backdrop of a pending reverse stock split to avoid Nasdaq delisting and a $353 million note maturity in October 2026, the results show a business stabilizing profitability but still shrinking — a mixed picture for a company fighting to regain compliance and manage its debt load.